ADMA Biologics (ADMA) Projected to Post Quarterly Earnings on Wednesday

ADMA Biologics (NASDAQ:ADMA) is expected to be announcing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect ADMA Biologics to post earnings of $0.1967 per share and revenue of $138.11 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.16 EPS for the quarter, meeting the consensus estimate of $0.16. The firm had revenue of $124.39 million during the quarter, compared to analysts’ expectations of $125.34 million. During the same quarter last year, the business posted $0.14 EPS. The company’s quarterly revenue was up 2.0% on a year-over-year basis. On average, analysts expect ADMA Biologics to post $0.78 EPS for the current fiscal year and $0.85 EPS for the next fiscal year.

ADMA Biologics Stock Performance

Shares of NASDAQ ADMA opened at $11.17 on Wednesday. ADMA Biologics has a twelve month low of $7.21 and a twelve month high of $20.46. The stock’s 50 day moving average price is $9.90 and its 200-day moving average price is $11.13.

Wall Street Analyst Weigh In

Several research analysts have weighed in on ADMA shares. Zacks Research raised ADMA Biologics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, September 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a research report on Monday, September 14th. Finally, Mizuho lowered their target price on ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 15th. Three analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $18.67.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company focused on developing, manufacturing and commercializing plasma-derived biologic products for people with compromised or weakened immune systems. The company’s activities include collecting human plasma, developing immune globulin therapies and manufacturing products for use in the prevention and treatment of certain infectious diseases.

ADMA’s portfolio includes Asceniv, an intravenous immune globulin indicated for primary humoral immunodeficiency disease, and Bivigam, an intravenous immune globulin used for the treatment of primary humoral immunodeficiency.